Calla Lily Clinical Care

• ·Developer of women-specific drug-delivery systems designed to improve patient outcomes.
• ·Calla Lily Clinical Care is valued at approximately $14.4M as of Oct 2026 (last reported valuation).
• ·It has raised $6.9M across 1 recorded rounds; the latest was Accelerator/Incubator in Mar 2025.
• ·Notable investors include Innovate UK, Springboard Enterprises, Conduit Connect, HH Global Partners, Science Center.
• ·Status: Privately Held (backing).

Developer of women-specific drug-delivery systems designed to improve patient outcomes. The company specializes in patented vaginal drug delivery devices to broad range of therapeutics targeting fertility, gynecological cancers, and vaginal microbiome, it offers a drug-device combo product to prevent miscarriages and for In Vitro Fertilization luteal phase support and can also deliver live biotherapeutics to reduce recurrent Bacterial Vaginosis, cutting antibiotic usage, enabling patients to access a safer and patient-friendlier way of progesterone administration which reduces the spread of antimicrobial resistance.

Industry

Drug Delivery

Sector

Healthcare

HQ

London, United Kingdom

Founded

2021

Employees

32

Website

callali.ly/

Ownership

Privately Held (backing)